← Back to Search

Proteasome Inhibitor

Group A for Transplant/Implant

Phase 1 & 2
Waitlist Available
Led By Ervin S Woodle, MD
Research Sponsored by E. Steve Woodle
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 44 days
Awards & highlights

Study Summary

This trial will test the safety of a new drug combo to help kidney transplant patients with HLA antibodies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 44 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 44 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent reduction in immunodominant Donor Specific Antibody (iDSA) [highest titer DSA (MFI)] and/or immunodominant antibody (iAb)

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group CExperimental Treatment3 Interventions
6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
Group II: Group BExperimental Treatment3 Interventions
4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
Group III: Group AExperimental Treatment2 Interventions
4 doses of plerixafor and plasmapheresis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bortezomib D-mannitol
FDA approved
Plerixafor
FDA approved

Find a Location

Who is running the clinical trial?

E. Steve WoodleLead Sponsor
2 Previous Clinical Trials
43 Total Patients Enrolled
Sanofi-SynthelaboIndustry Sponsor
49 Previous Clinical Trials
34,654 Total Patients Enrolled
Ervin S Woodle, MDPrincipal InvestigatorUniversity of Cincinnati

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Quantitating the Impact of Plerixafor
E. Steve Woodle 2015. "Quantitating the Impact of Plerixafor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02522572.
All > Velcade
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top